Facebook
Linkedin
Twitter
Industries
Aerospace
Agritech
Automotive
BFSI
Biotechnology
Chemicals
Defence Technology
Energy, Power and Sustainability
Food & Beverage
Healthcare
Information Technology
MarTech
Internet Of Things (IOT)
Logistics and Supply Chain
Materials
Medical Devices
Retail
Semiconductor & Electronics
Smart Lighting
Latest News
Interviews
Insights
Guest Post
Staff Writer
Featured Article
Quick Byte
Resources
Search
Friday, April 4, 2025
Facebook
Linkedin
Twitter
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
ReadMagazine
Industries
All
Aerospace
Agritech
Automotive
BFSI
Biotechnology
Chemicals
Defence Technology
Energy, Power and Sustainability
Food & Beverage
Healthcare
Information Technology
MarTech
Internet Of Things (IOT)
Logistics and Supply Chain
Materials
Medical Devices
Retail
Semiconductor & Electronics
Smart Lighting
Solera Unveils AI-Driven Fleet Management Platform
Culture Biosciences Unveils Stratyx™ 250: The First Cloud-Integrated, Mobile Bioreactor for…
PANTHERx® Rare Expands Patient Support Capabilities for Cell and Gene Therapies…
IRBM Expands Functional Genomics Platform to Strengthen Early Drug Discovery
Latest News
Interviews
Insights
Guest Post
Staff Writer
Featured Article
Quick Byte
Resources
Home
Tags
Cerebral amyloid angiopathy
cerebral amyloid angiopathy
Biotechnology
Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Business Wire
-
April 28, 2023
Alnylam Pharmaceuticals, Inc. and Regeneron Pharmaceuticals, Inc. announced positive interim results from the ongoing single ascending dose part of the Phase 1 study of...
0
Fans
Like
3,912
Followers
Follow
0
Subscribers
Subscribe
Hot Topics
Solera Unveils AI-Driven Fleet Management Platform
Culture Biosciences Unveils Stratyx™ 250: The First Cloud-Integrated, Mobile Bioreactor for Accelerated Cell Culture Development
PANTHERx® Rare Expands Patient Support Capabilities for Cell and Gene Therapies with RxARECONCIERGE™
Load more
